Compare Amylx Pharmaceuticals Inc (AMLX) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.67 (market cap $2.64B), while ProShares UltraPro Short QQQ ETF trades at $37.1. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | SQQQ | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $24.19 | $92.95 |
52-Week Low | $7.82 | $36.31 |
Enterprise Value | $2.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
SQQQ trades at $37.05, down 1.83% on the day, reflecting its inverse leveraged structure designed to move opposite the Nasdaq-100. The technical picture remains bearish with moving averages signaling continued downward pressure, though oversold conditions suggest potential for short-term bounces. Recent news highlights SQQQ's role as a tactical hedging tool rather than a long-term investment, with significant erosion risk due to daily reset mechanisms.
SQQQ serves as a high-risk tactical instrument for bearish Nasdaq-100 bets, with success dependent on precise market timing. The ETF faces structural decay from daily rebalancing, making it unsuitable for buy-and-hold strategies. Current market volatility and tech sector concerns create potential short-term opportunities, but long-term holders have historically suffered substantial losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
